Guía OncoSur de Cáncer de mama 60 > BIBLIOGRAFÍA 1. MacDonald KV, Bombard Y, Deal K, Trudeau M, Leighl N, Marshall DA. The influence of gene expression profiling on decisional conflicto in decision making for early-stage breast cancer chemotherapy. Eur J Cancer. 2016;61:85-93. 2. Harris LN, Ismaila N, McShane LM, Andre F, Collyar DE, González Angulo AM, et al. Use of biomarker to Guide Decisions on adjuvant Systemic Therapy for Women with Early-Stage Invasive Breast Cancer: American Society of Clinical Oncology Clinical Practice Guideline. J Clin Oncol. 2016;34:1134. 3. Bartlett JM, Bayani J, Marshall A, Dunn JA, Campbell A, Cunningham C, et al. Comparing Breast Cancer Multiparameter Test in the OPTIMA Prelim Trial: no Test is More Equal than the others. J Natl Cancer Inst. 2016;29;108(9). 4. Paik S, Tang G, Shak S, Kim C, Baker J, Kim W, et al. Gene expression and benefit of chemotherapy in women with node negative, estrogen receptor-positive breast cáncer. J Clin Oncol 2006;24(23):3726-34. 5. Sparano JA, Gray RJ, Makower DF, Pritchard KI, Albain KS, Hayes DF, et al. Adjuvant Chemotherapy Guided by a 21-Gene expression Assay in Breast Cancer. N Engl J Med. 2018 Jul;379(2):111-21. 6. Filipits M, Rudas M, Jakesz R, Dubsky P, Fitzal F, Singer CF, et al. A new molecular predictor of distant recurrence in ER-positive, HER2 negative breast cancer adds independent information to conventional clinical risk factors. Clin Cancer Res. 2011;17(18):6012-20. 7. Sgroi DC, Carney E, Zarrella E, Steffel L, Binns SN, Finkelstein DM, et al. Prediction of late disease recurrence and extended adjuvant letrozole benefit by the HOXB13/IL17BR biomarker. J Natl Cancer Inst. 2013;105(14):1036-42. 8. Jansen MP, Sieuwerts AM, Look MP, Ritstier K, Meijer-van Gelder ME, van Staveren IL, et al. HOXB13-toIL17BR expression ratio is related with tumor aggressiveness and response to tamoxifen of recurrence breast cancer: a retrospective study. J Clin Oncol. 2007;25(6):662-8. 9. Sgroi DC, Sestak I, Cuzick J, Zhang Y, Schnabel CA, Schroeder B, et al. Prediction of late distant recurrence in patients with oestrogen-receptor positive breast cancer: a prospective comparison of the breast cáncer index (BCI) assay, 21-gene recurrence score and IHC4 in the Trans ATAC study population. Lancet Oncol. 2013;14(11):1067-76. 10. Nielsen TO, Parker JS, Leung S, Voduc D, Ebbert M, Vickery T, et al. A comparison of PAM50 intrinsic subtyping with immunohistochemistry and clinical prognostic factors in tamoxifen-treated estrogen receptor-positive breast cáncer. Clin Cancer Res. 2010;16(21):5222-32. 11. Chia SK, Bramwell VH, Tu D, Shepherd LE, Jiang S, Vickery T, et al. A 50-gene intrinsic sbtype classifier for prognosis and prediction of benefit from adjuvant tamoxifen. Clin Cancer Res. 2012;15;18(16):4465-72. 12. Pérez EA, Ballman KV, Mashadi-Hossein A, Tenner KS, Kachergus JM, Norton N, et al. Intrinsic subtype and Therapeutic Response Among HER2 Positive Breast Tumors from the NCCTG (Alliance) N9831 Trial. J Natl Cancer Inst. 2017;109(2):djw207. 13. Piccart M, Rutgers E, Van´t Veert L, Delaloge S, Veer LV, Rubio IT, et al. Primary analysis of the EORTC 10041/ BIG 3-04 MINDACT sudy: a prospective, randomized study evaluating the clinical utility of the 70-gene signature (MammaPrint) combined with common clinical-pathological criteria for selection of patients for adjuvant chemotheraoy in breas cacer with 0 to 3 positive nodes. Cancer Res. 2016;76S:AACR CT039.
RkJQdWJsaXNoZXIy MTQzMjMwMg==